A First-in-Human Single and Multiple Ascending Dose Study of MT-501

Phase 1

Recruiting

• Conditions: Healthy Volunteers
• Interventions: Drug: MT-501

• Registration Number: NCT06762457
• Lead Sponsor: Mirador Therapeutics, Inc.

Brief Summary

First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.

Detailed Description

This study is the first administration of MT-501 in healthy volunteers (HV). The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of up to 8 days of MT-501 in HV. The safety, tolerability, PK, and PD data obtained from this study will inform further development of MT-501.

Study Timeline

• Study Start: 2024-12-11
• Study First Submitted: 2024-12-31
• Study First Submitted QC: 2024-12-31
• Status Verified: 2025-01
• Study First Posted: 2025-01-07
• Last Update Submitted: 2025-01-07
• Last Update Posted: 2025-01-09
• Primary Completion: 2025-06
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

1. Male or female (of non-childbearing potential only) between 19 and 55 years of age inclusive, at the time of signing informed consent.
2. Females must be of non-childbearing potential and must have undergone sterilization procedures, and have official documentation, at least 6 months prior to the first dose.
3. Male subjects must use highly effective forms of contraception during sexual intercourse with female partners of childbearing potential. A non-vasectomized, male subject must agree to use a condom with a chemical barrier method.
4. Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the first dose of drug.
5. Good general health.
6. Able to provide written informed consent and understand and comply with the requirements of the study.

Exclusion Criteria

1. History or presence of any clinically significant organ system disease.
2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.
3. History of alcohol or drug abuse within the past 24 months.
4. Current use or history of regular tobacco, or nicotine-containing products within 3 months prior to screening.
5. Administration or use of any investigational drug or device within 30 days preceding the first does of study drug administration.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Part 1 - Single Ascending Dose	MT-501	To assess the safety and tolerability of single doses of MT-501 following oral administration.
Part 2 - Multiple Ascending Dose	MT-501	To assess the safety and tolerability of multiple doses of MT-501 following oral administration.

Primary Outcome Measures

Name	Time	Method
Primary Outcome Measure: Number of Subjects with non-SAEs and SAES	Up to 14 days post dose	Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.

Trial Locations

Locations (1)

Mirador Clinical Department; 🇺🇸 San Diego, California, United States